Participate in a Study - Currently Recruiting

The Clinical Research Unit serves as a place where basic and clinical scientists work together to perform studies that incorporate translational research (the process of making research findings benefit patients) resulting in meaningful health outcomes. The Clinical Research Unit, along with skilled researchers and coordinators, will provide a welcoming and proficient setting for participants to volunteer in groundbreaking research studies.


Once weekly growth hormone therapy

—Andrea Haqq

Researchers at the University of Alberta are investigating whether a new type of growth hormone therapy that is injected once a week is as safe and effective as the standard daily injection of growth hormone that is normally used to treat children with Growth Hormone Deficiency

Inclusion criteria:

  • between the age of 3-10 years (for girls), or 3-11 years (for boys)
  • has growth failure due to growth hormone deficiency
For more information please contact:
Kristie DeHann 780-492-1098

PBI-4050-CT-9-08: A study for adults who have Type 2 diabetes with metabolic syndrome

—Dr Peter Senior

This research study is investigating whether or not an investigational drug can improve blood sugar control and the general health of people who have Type 2 diabetes with metabolic syndrome.

You may qualify for the study if:

  • You have Type 2 diabetes
  • You are taking oral medication for your diabetes, and/or are using long-acting insulin
  • You have any of the following:
    - Abdominal obesity (large waist)
    - High triglycerides
    - Low HDL-C (“good” cholesterol)
    - High blood pressure
    - High fasting blood sugar
For more information, please contact the ADI Clinical Research Unit:
Kristie DeHann  780-492-1098
Caroline Lyster  780-­248-­1770

Sponsored by ProMetic Pharma SMT Ltd

Genetic Testing of Obese Children and Adults 

—Andrea Haqq

Genes are often called “DNA” and are found in the body, making every individual different from anyone else. Some genes control things like the color of the hair or eyes. Other genes might make people more likely to weigh more. 

The purpose of this study is to identify people who have a rare genetic cause of obesity, who are 2 years of age or older. 

Participants will come to the University of Alberta for a one-hour visit. 

Participants will be asked questions about their health and appetite. Next, we will collect a blood sample from their arm. This screening test will identify individuals with one of three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that is currently known to result in obesity. 

Inclusion criteria:

  • Evidence of hunger/hyperphagia at screening
  • Severe childhood obesity, preferably with past history evidence suggestive of onset prior to age 6 years at the time of identification

For more information please contact:  Lucila at
Sponsored by Rhythm Pharmaceuticals, Inc.

GLARGL07699 Study

Effect of switching from a twice-daily injection of basal insulin to a once-daily injection of ToujeoTM in adults with Type 1 diabetes

– Peter Senior/sanofi-aventis Canada Inc

Post-marketing drug trial for patients with Type 1 diabetes who use a twice-daily injection of basal insulin.

Contact the ADI Clinical Research Unit for more information or for prescreening:
Caroline Lyster       780-­248-­1770


Polycystic Ovary Syndrome (PCOS) Clinical Trial

—Donna Vine

  • Women with a diagnosis of Polycystic Ovary Syndrome
  • Overweight or obese
  • 18-30 years old 
  • Exclusion Criteria: Pregnancy, lactating, taking oral contraceptives or medication that influences metabolism (eg statins)

For more information please contact:
Stara Morning (Study Coordinator)       780-238-5111
Donna Vine    (Principle Investigator)   780-492-4393

The Alberta FYBER Study (Feed Your Gut Bacteria More FIber)

—Jens Walter

  • A randomized control trial studying the role of fiber in gut health 
  • Healthy males or females ages 19-45 years old with a BMI between 25-35
  • Participants will be asked to add pre-packaged fiber to their diet daily for a period of six weeks

For more information please contact: or 780-492-9506  


The VIGOR Trial

A study examining the effects of physical fitness on glycemic responses to high intensity exercise in type 1 diabetes.

—Jane Yardley

Males and females with type 1 diabetes:

  • between the ages of 15 and 35
  • regularly participating in vigorous endurance exercise (> or equal to 3 times/week for >1 year)
  • having an HbA1c < 9.9%

For more information please contact: 
Jane Yardley

Blood Glucose Responses to Resistance Exercise in Type 1 Diabetes

Males and females with type 1 diabetes:
  • Between the ages of 18 and 50 
  • Regularly performing physical activity at least three times/week
  • Having HbA1c < 9.9%
For more information please contact: 
Jane Yardley

Impact of exercise during pregnancy on blood pressure control study

—Margie Davenport

  • Less than 20 weeks pregnant
For more information or to volunteer please contact: or phone 780-492-0642

Blood Pressure Regulation During Pregnancy 

—Margie Davenport

  • Recruiting women with either 1) normal blood pressure 2) gestational hypertension 3) preeclampsia or 4) gestational diabetes
  • Testing occurs after 28 weeks 

For more information or to volunteer please contact: or phone 780-492-0642 

E-PAraDiGM: Exercise-Physical Activity Diabetes Glucose Monitoring Protocol 

  • Men and women with type 2 diabetes   
  • 30-90 years of age   
  • HbA1c < 9%   
  • Able to walk for 45 minutes    
For more information contact Jordan Rees

Join our participant database

Interested in participating in research, but don’t qualify for any of our current studies? 
Sign up for our general database using our Google form

Your information will be entered into our database, and researchers may contact you about participation in future research studies at the Alberta Diabetes Institute.